Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why not describe it accurately - it was not a forecast, it was a BHAG - to be a billion dollar company in 5 years.
$SIRC Solar Integrated Roofing is an emerging growth company and though we have substantial revenue, it's still very early on the exponential growth curve. The market is forward-looking AND speculative. And fundamentals have much less impact on peak pricing than does speculation, for small growth companies.
Until you see a more boring track record of positive earnings Q after Q after Q, it's almost ALL about speculation - about the future company performance and growth AND the market/sector. This is a hot market sector, and is likely to become much hotter as we know due to the market environment, including the global thirst for all things "green" or "alternative" - especially including solar - as well as the huge upcoming govt "infrastructure" spend.
So I agree completely with Trip, your numbers are very conservative and, unless you are treating your stock positions like a long-hold mutual fund in your 401k... you should be more interested in estimating the highs and lows, NOT the "fair market value." Look around, you will rarely see a nano-cap or micro-cap growth company resting at what you might be able to calculate as a fair market value. The market speculates. And sometimes the high/low range expands GREATLY - like now. You should be looking to hold for higher prices when the market generally supports higher prices (as it does this year); and just the same, you should take some profits at those high prices if/when the market begins a correction.
$SIRC Nice day here, I'm enjoying the steady work of the company and forward outlook!
I'm very happy with the Q2 results, and the information provided in the conference call. What I "got" from the con call is EXACTLY what I wanted to know!
#A - the financing/dilution... we were updated on the status, and I'm not concerned at all; we all understand this pretty well by now (or, at least anyone investing here or with any nano-cap stocks should clearly understand such things, and where RXMD is with financing right now). I wasn't expecting anything new here, nor did anyone that knows a thing or two.
Now the more important real info that goes to telling me the value and near-term potential upside for the stock:
#1 - explanation of S1 status: 1 question only from SEC in the latest (3rd) round of back-and-forth
#2 - confirmation of uplist plan still in place: still the plan, still within 2021
#3 - update on uplist plan status and catalyst for proceeding: new investment banker that they believe will get the job done
#4 - management declared the diversification plan and strategy to be THE plan, after successful 340B contract services BETA project that yielded SUBSTANTIAL revenue ($1.4M over 1st 6 months of 2021) and 127% growth y-o-y.
#5 - management committed to plan for Nationwide Rollout of 340B Contract Services business in Q1 of 2022
#6 - management has made it a serious goal to be a $1B diversified healthcare technology services business within 5 years
Great stuff, glad to be here!
About $660,000 less than March 31, 2021.
Now let's talk about a projection for nationwide rollout for those 340B services!!! Think about the growth from nationwide! And now think about the growth nationwide on top of proven growth (127% y-o-y) from the Beta/pilot program only locally! Buy RXMD
340B contract revenue for six months ended June 30, 2021 was $1,449,820. This represents growth of 127% over the $639,455 for the same period last year!!!!!!!
Talking about management's diversification strategy strongly validated, as can be seen in the 340B results... and so setting out on trajectory for Q1 2022 nationwide rollout. Will discuss further later in this conference call.
It's here - in the press release. Just go to the link and input your info:
https://www.otcmarkets.com/stock/RXMD/news/Progressive-Care-to-Announce-Second-Quarter-2021-Financial-Results-and-Provide-Business-Update?id=316000
Agreed, all pretty decent.
Not exactly. I noticed that you rounded down. I prefer being more precise, or at least to round up/down according to normal/conventional mathematical/statistical practice.
The actual increase in revenue for the 3 month period compared to last year was $371,851. That's a 4% gain. If you take the 6-month period, it's more like 5%, which is comparable to the Q1 results for both CVS and Walgreen-Boots Alliance, which are nearly 6%. (I haven't seen or reviewed Q2 results for those companies, so this is good for a quick comparison)
It's been argued - factually - that smaller companies have been impacted MUCH more significantly by COVID-19 AND the current administration (through their policies and the resulting effects on labor and product supply/chains) than large corporations, so I give Progressive Care / PharmcoRX kudos for a solid performance this year to-date as well as last year!!
$KHRNF I think it can only be positive. I know I will be listening carefully for any kind of guidance in future news releases, and now sure seems to be a better time to be building a stronger position than waiting for that news.
$PRTY Time to wind... buy opp!
$ALPP Share structure - no change. Thanks for posting.
Great news! Top notch IR for product launch and campaign to bring near term stock pps growth value to investors!!
$IPSI Yes, it really is coming together. The business/product launch revving, management/corporate and IR setup finessing, and it looks like the news cycle is warming up to gel with perfect market timing as folks are just now beginning to load their positions for the seasonal influx. Add to that the continuing fiscal stimulus and a potentially humongous spending plan from the U.S. Admin and we're going to have a LOT of money moving everywhere (good for the product), including the markets (good for the stock).
$JUSHF Awesome! 219.7% year-over-year revenue increase, Q2=$47.7 million.
And to be sure... there is a lot of interest in this company.
$KHRNF Trading activity points to serious interest, and I'm not surprised. I've been loading for a while, and it's only to be expected that many others are hoping to load in this range before the broader market becomes aware.
I don't care what you buy into. But rather than obfuscate, why not address the subject, which was to state the situation correctly. To say that insiders are giving themselves Stock Options at an exercise price of $0.01 is not only misleading, it's absolutely UNTRUE.
As I stated previously, these Stock Options are worthless until the pps rises substantially.
I am quite satisfied with the incentive plan, and how the insiders' motivations - per the stock option incentive plan - are aligned with my interests as a shareholder. When those options are valuable enough to be worth exercising, my personal ZNOG position will have substantial gains... and the kicker is that I, as well as any/all retail investors will be able to easily sell into the market well before insiders, if I so choose.
Furthermore, in any reasonable scenario involving substantial gains in the stock price due to oil discovery, insiders with substantial holdings will most likely take their profits through an uplist IPO or through the sale of (control of) the company or other control/licensing transaction - not by selling through retail channels. That is just Exit Planning 101. Investors, retail or otherwise, should know these things. I do.
Further to the point, all directors and other insiders are incentivized to help the company SUCCEED in general. Until the stock price is sufficiently high AND there is sufficient liquidity (volume), this is simply no way for these individuals to reap any proceeds of significance from the sale of stock. And as previously noted, these options that were awarded are worth very little until stock price is SUBSTANTIALLY HIGHER than $0.3912.
$ZNOG Well, that's not exactly how it works, as it is stated clearly in various filings, regarding "ZION OIL & GAS, INC. 2021 OMNIBUS INCENTIVE PLAN."
If fact, the Form 4 shows exactly the exercise price, and it's NOT $0.01. $0.01 is the par value of the common stock shares. The exercise price shown in the Form 4 filed today for Brad Dacus (Director), for example, is $0.3912, which was the market closing price on 7/9/2021, the date that the shares were awarded.
https://www.otcmarkets.com/filing/html?id=15120080&guid=_YKkk6Z1JfCNKth
The exercise price of $0.3912 is in keeping with the Incentive Plan and, in fact, it incentivizes the Director to contribute in whatever way possible toward maximizing the market price of the Common Stock. These options are WORTHLESS until the price exceeds $0.3912, since that is the exercise price (the price that Dacus must pay for the shares).
When the price reaches $0.50, for example, those 100K shares will be worth ($0.50 - $0.3912) x 100,000 = $10,880.
When the price reaches $1, those 100K shares will be worth ($1 - $0.3912) x 100,000 = $60,880.
Excerpts relevant to this discussion:
$FLGC What great timing, that was a fast run-up. Hit double digits already!
Right on, RIO!
$FLGC Huge move EOD, halted @ 3:40 and didn't resume until AH. Hoping for a gap down at open before further movement, would be nice for adding.
$FLGC Argus Research Initiates Equity Research Report Coverage on Flora Growth Corp. (NASDAQ: FLGC)
https://www.prnewswire.com/news-releases/argus-research-initiates-equity-research-report-coverage-on-flora-growth-corp-nasdaq-flgc-301340523.html
NEW YORK, July 26, 2021 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Flora Growth Corp. (NASDAQ: FLGC)
COMPANY HIGHLIGHTS: Excerpts (as conveyed by Argus Analyst Steve Silver) include:
FLGC: A Fast-Growing Global Cannabis Cultivator and Brand Builder
Flora Growth leverages cost-effective cannabis cultivation in Colombia to supply cannabis and its derivatives for an expanding range of products, including cosmetics, pharmaceuticals, food and beverages, and hemp-based textiles.
The company's outdoor cultivation operation in Colombia — along the equator and at an altitude of 1500 meters above sea level — benefits from favorable weather that allows for year-round organic growing.
Flora's production costs are also significantly lower than those of its Colombian peers, at less than $0.06 per gram.
To complement its cultivation capabilities, Flora is building an extraction and processing facility in Colombia. It is also developing a wholesale cannabis distribution business, and is expanding internationally through acquisitions and partnerships.
In our view, Flora Growth is well capitalized, with $30 million in proceeds from a December 2020 private financing, $16.6 million in IPO proceeds, and the expected infusion of more than $20 million from the exercise of warrants.
We believe that Flora is attractively valued relative to peers based on its low cost structure, strong brand portfolio, and expanding global distribution. Based on our EV/revenue analysis, our fair value estimate for FLGC is $7.50 per share, more than two-times current levels.
Founded in 2019, Flora Growth leverages cost-effective cannabis cultivation in Colombia to supply cannabis and its derivatives for an expanding range of products, including cosmetics, pharmaceuticals, food and beverages, and hemp-based textiles.
In our view, Flora Growth is well positioned to participate in a global cannabis market that BDS Analytics projects will reach $56 billion by 2026, up from $21 billion in 2020. The company's outdoor cultivation operation in Colombia — along the equator and at an altitude of 1500 meters above sea level — benefits from favorable weather that allows for year-round organic growing, and is expected to yield three annual crop cycles, compared with 1-2 cycles in other regions. These operations also have low water and electricity costs. Due to the open-air cultivation, its crop has shown more-robust growth yields over greenhouse cultivated crops, and a richer terpene profile, which enhances the flower's aroma. Flora's operations also benefit from a highly skilled agricultural workforce, with labor costs that are approximately 10% of those for comparable operations in the United States.
https://www.argusresearch.com/
Argus Initiates Sponsored Research Coverage 7/22/2021
Argus Sponsored Research ReportsFlora Growth Corp. (NASDAQ: FLGC)
https://www.argusresearch.com/PDFDownloader3.aspx?id=MDAwMDAwOTk3OA==aAB0AHQAcAA6AC8ALwByAGUAcwBvAHUAcgBjAGUAcwAuAGEAcgBnAHUAcwByAGUAcwBlAGEAcgBjAGgALgBjAG8AbQAvAHIAZQBwAG8AcgB0AHMALwAwADAALwAwADAALwA2ADAALwA5ADIALwAxADAALQA1AEYAOQBEAEMARQBEAEQALQAwADUARAA0AC0ANAAyADMAQQAtAEIAQwAyADIALQAzAEMAMgA4ADUARgAwAEUAQwA5ADEANgAuAHAAZABmAA==
Double digit price and triple digit growth on the horizon!
$FLGC Awesome news! Flora Growth Applauds Update to Colombian Cannabis Regulations that Substantially Increases Revenue Potential; Executes International Cannabis Supply Agreement
https://www.businesswire.com/news/home/20210726005350/en/Flora-Growth-Applauds-Update-to-Colombian-Cannabis-Regulations-that-Substantially-Increases-Revenue-Potential-Executes-International-Cannabis-Supply-Agreement
$KHRNF MORE awesome news!! A great read on a Sunday morning, this news came out 5 minutes after the market closed on Friday.
https://www.reuters.com/world/americas/colombia-boosts-budding-cannabis-industry-by-removing-ban-dry-flower-exports-2021-07-23/
$OWPC Absolutely HUGE!! A great read on a Sunday morning, this news came out 5 minutes after the market closed on Friday.
https://www.reuters.com/world/americas/colombia-boosts-budding-cannabis-industry-by-removing-ban-dry-flower-exports-2021-07-23/
$OWPC Good summary of the forward look here. And that's just starting. I think new inroads and new deals will be coming on a regular basis once this machine starts firing on all cylinders - which is right around the corner now. I think it starts with the coming news cycle supported by the new IR firm.
$OWPC Right. And not just some rinky dink IR group. Take a look at the CoreIR team:
https://coreir.com/our-team/
$3M investment by CEO just completed, milestones recently achieved with authorizations from Colombia regulatory including new revenue opportunities plus first revenue news on the way...
OWPC is getting set to move, just a matter of time now.
Lol, first get a clue who you are talking ABOUT. Clearly you've never talked with Armen. Second get a clue who you're talking TO. Then let me know when you have something useful to add, I like to stay tuned in.
Sorry, SF, but this does not make sense and does not jibe with my experience/discussions with Armen, nor with how financing works. You don't put the cart before the horse, and Armen understands that.
There's a reason why the company stopped SEC reporting. It's VERY expensive (relative to alternative reporting via OTC Markets), and for a small company it is also very taxing on limited resources and for these two reasons adds undue risk to small business growth plans - which ALL small businesses need to prioritize highly until they achieve a certain threshold of operations relative to their achievable growth plan. As we can all see from the trend and the results over the past 6 years, Progressive Care / PharmcoRX has been successful in making major milestones along their growth trajectory, and the "achievable growth plan" (as I phrased it) is showing no upper boundary anywhere in sight.
Now, step back and look at where we might be if the priority was to resume SEC reporting, rather than continue on this growth trajectory... you could probably erase the past 2-3 years of added value, and the company would be still be struggling just to achieve one or two of those milestones that are far in the rear view by now, with much lower revenue and far from profitable - but they'd be SEC reporting.
The company IS clearing the note, AS WELL AS actively pursuing improved reporting and listing, and has never had a better financial AND growth posture. Now is not the time (imo) to get excited with arms flailing, (imo) it's the time to take heart and look positively at the future that's within arm's reach, for turning the corner toward Wall Street with a strong and convincing value and growth proposition.
I know you've been around for quite a long time, and I understand the impatience. But I've also been around a long time, and I stand by Armen. Early on, I didn't know Armen and couldn't trust someone I didn't know, so I called him whenever I was uncomfortable about 'why' or 'what for'. It's been a few years since I've felt the need to call him. I have all I need in the filings, and I'm very comfortable with my position (stock holdings), but I still find funds to add more just about every week. Just sayin'... there are shareholders out there who are patient and quite happy with this investment. Even if it takes longer than I'd like. I really just want to make a killing and build multi-generational wealth in just a few short months or years, but... I'd rather invest in great businesses with enormous growth potential than put my hard-earned money on a betting line or the lottery.
I don't think so, SF. I believe they will need to file a Form 10 at the time that they resume SEC reporting. There are other requirements for that reporting, I believe including current filings for the past 2 years. The Form 10 wraps everything.
On 3/18/2015 the company filed Form 15-12G, formally terminating their SEC reporting at that time:
$IPSI It appears that Corbett is continuing to strengthen the business for the full launch, now apparently working on The Board.
Note that "Following his resignation Mr. Novikov (previously employed as a Vice President-International Business Development by Qiwi Plc) has continued to serve as the Company’s Chief Technology Officer."
So now there is an opening on The Board, as well as the corporate Secretary position.
The Secretary AND CTO position to me seemed clearly to be a temporary situation and "placeholder" to later fill appropriately as the business is ready for full launch when the business can support a strengthening of the corporate management structure.
I think we'll see another announcement/disclosure soon regarding the disposition of that vacant Board seat.
$OWPC I do believe you are right about that. $3M invested for preferred shares equivalent to Common at 0.15.
When the CEO is investing $3M of his own money - locked in preferreds - I'm paying close attention and loading for the big future payday as well!
Not only that, gedi, the 10% is imo most likely stated as '10% of the average daily volume on a rolling weekly basis (5-day average, 7-day average, 10-day or whatever).' That's the way I've seen it written in note contracts, and I'd be very surprised if the Iliad note called for something as granular as a daily maximum. Such a limitation would be almost impossible to follow and/or enforce with most nano- and micro-cap stocks, as they simply trade too thinly. Just think about it, and you can't imagine how a lender/financier would ever be able to agree and abide by such terms.
I haven't been paying too damn close attention to the daily details here, but I'm sure someone here on the board has the daily T-trades in a spreadsheet and they likely know very well whether we're seeing roughly an average of 10% over a week's time. If that's what we're seeing... mystery solved; if not, then there are plenty of ideas to speculate about.
Whatever the case, those that have more detailed info/records tend to keep it selfishly close and use it to their advantage - can't blame 'em. But we can all see a recent bottom and a trend reversal, so we may not be far from the end of the cheap dilutive shares and a rapid/accelerating price recovery. Anyone wasting their time all day to work sentiment to flip for a few burgers is really wasting precious time of their lives while the rest of us practice patience and build wealth.
$KHRNF Awesome news - continuing to move rapidly forward!